Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Numinus Wellness Inc. (T:NUMI)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
Company Contact
Address: 393 Laurier Ave W
Tel: N/A
IR: See website
Key People
Payton Nyquvest
President, Chief Executive Officer, Director
Nikhil Handa
Chief Financial Officer
Michael Tan
Chief Operating Officer, Director
Devon Christie
Medical Director and Member of Clinical Advisory Council
Judy Varga
Head of Laboratory Operations
Stacey Wallin
Chief Strategy Officer
Evan Wood
Chief Medical Officer
Business Overview
Numinus Wellness Inc. (Numinus) is a Canada-based mental health care company. The Company develops proprietary, psychedelic-centered, therapeutic products and services through its own laboratory and research and development processes. The Company operates through three segments: Clinical Research Operations, the Canadian Clinic Network, the U.S. Clinic Network. Its Research Operations is focused on licensed psychedelic research and provides clinical research management services to academic institutions and biotechnology companies. Numinus clinic network in Canada consists of Numinus Health, Mindspace, and the NCT. Numinus clinic network in the United States consists of Cedar Psychiatry Inc. (Cedar Psychiatry) and Foundations for Change Inc. (FFC). Numinus clinic network provides services including ketamine-assisted psychotherapy (KAP) for depression, transcranial magnetic stimulation (TMS), neurological care and psychotherapy and counselling by registered psychologists.
Financial Overview
For the fiscal year ended 31 August 2023, Numinus Wellness Inc revenues increased from C$6.5M to C$23.2M. Net loss decreased 33% to C$30.3M. Revenues reflect US Clinic Network segment increase from C$3M to C$16.4M, Clinical research operations segment increase from C$749K to C$3.5M, United States segment increase from C$3.5M to C$19.9M, Canada segment increase of 10% to C$3.3M.
Reporting Currency: Canadian Dollars
Enterprise value: $33.36M as of Aug 31, 2023
Annual revenue (TTM): $23.18M as of Aug 31, 2023
EBITDA (TTM): -$24.13M as of Aug 31, 2023
Net annual income (TTM): -$30.26M as of Aug 31, 2023
Free cash flow (TTM): -$23.14M as of Aug 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 266,455,100 as of Aug 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization